Joshua K Ochieng
Overview
Explore the profile of Joshua K Ochieng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
120
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez B, Chen L, Li Y, Miao S, Peng D, Fradette J, et al.
Front Immunol
. 2023 Jul;
14:1161869.
PMID: 37449205
Introduction: Despite significant clinical advancement with the use of immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) there are still a major subset of patients that develop adaptive/acquired...
2.
Padhye A, Konen J, Rodriguez B, Fradette J, Ochieng J, Diao L, et al.
JCI Insight
. 2021 Jul;
6(17).
PMID: 34309585
Lack of sustained response to therapeutic agents in patients with KRAS-mutant lung cancer poses a major challenge and arises partly due to intratumor heterogeneity that defines phenotypically distinct tumor subpopulations....
3.
Peng D, Rodriguez B, Diao L, Gaudreau P, Padhye A, Konen J, et al.
Nat Commun
. 2021 May;
12(1):2606.
PMID: 33972557
Understanding resistance mechanisms to targeted therapies and immune checkpoint blockade in mutant KRAS lung cancers is critical to developing novel combination therapies and improving patient survival. Here, we show that...
4.
Shi Y, Tomczak K, Li J, Ochieng J, Lee Y, Haymaker C
Front Pharmacol
. 2021 Jan;
11:566401.
PMID: 33505304
Checkpoint inhibitors are widely used immunotherapies for advanced cancer. Nonetheless, checkpoint inhibitors have a relatively low response rate, work in a limited range of cancers, and have some unignorable side...
5.
Konen J, Rodriguez B, Padhye A, Ochieng J, Gibson L, Diao L, et al.
Cancer Res
. 2021 Jan;
81(5):1398-1412.
PMID: 33402388
The epithelial-to-mesenchymal transition (EMT) is a dynamic epigenetic reprogramming event that occurs in a subset of tumor cells and is an initiating step toward invasion and distant metastasis. The process...
6.
Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, et al.
Am J Respir Crit Care Med
. 2020 Jul;
203(1):90-101.
PMID: 32730093
Early pathogenesis of lung adenocarcinoma (LUAD) remains largely unknown. We found that, relative to wild-type littermates, the innate immunomodulator (lipocalin-2) was increased in normal airways from mice with knockout of...
7.
Ochieng J, Schilders K, Kool H, Boerema-de Munck A, Buscop-van Kempen M, Gontan C, et al.
Am J Respir Cell Mol Biol
. 2014 Mar;
51(2):311-22.
PMID: 24669837
Lung development is determined by the coordinated expression of several key genes. Previously, we and others have shown the importance of the sex determining region Y-box 2 (Sox2) gene in...